Nuvation Bio Inc.
Income Statement
| Line Item | FY2025 | FY2024 | FY2023 |
|---|---|---|---|
| Revenue | $62.9M | $7.9M | $0 |
| Cost of Revenue | — | $7.1M | $0 |
| Gross Profit | — | $795.0K | $0 |
| Gross Margin | — | 10.1% | — |
| Operating Expenses | |||
| Research & Development | $115.1M | $99.1M | $71.3M |
| SG&A Expense | $151.6M | $69.2M | $28.5M |
| Operating Income | $-213.1M | $-592.6M | $-99.8M |
| Operating Margin | -338.7% | -7,527.3% | — |
| Interest Expense | — | — | — |
| Pretax Income | $-204.6M | $-567.9M | $-75.8M |
| Income Tax Expense | $0 | $0 | $0 |
| Net Income | $-204.6M | $-567.9M | $-75.8M |
| Net Margin | -325.3% | -7,213.8% | — |
| EPS (Basic) | $-0.60 | $-2.11 | $-0.35 |
| EPS (Diluted) | $-0.60 | $-2.11 | $-0.35 |
| Shares Outstanding (Basic) | 341.5K | 268.8K | 218.9K |
| Shares Outstanding (Diluted) | 341.5K | 268.8K | 218.9K |
| Dividends Per Share | — | — | — |